Briefing
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions (CLL14)
Phase 3 first-line venetoclax-obinutuzumab vs chlorambucil-obinutuzumab in patients with CLL and coexisting conditions. Fixed-duration Ven-O produced high MRD-undetectable rates and a PFS benefit, with subsequent MRD-dynamics papers (Al-Sawaf JCO 2021; 6-year Blood 2024). Level 2.
- Design: paper
- Assay: Undetectable MRD as a key depth-of-response endpoint (fixed-duration Ven-O vs Clb-O)